The general office of the Standing Committee of the National People's Congress held a special press conference on the vaccine management law, attended by Jiao Hong and pointed out that the strictest management system should be implemented for vaccines

On June 29, the vaccine management law of the people's Republic of China was adopted by the 11th meeting of the Standing Committee of the 13th National People's Congress In the afternoon of that day, the general office of the Standing Committee of the National People's Congress held a press conference with the vaccine management law as a special topic Jiao Hong, director of the State Food and drug administration, attended the conference and answered questions from reporters Jiao Hong pointed out that the "vaccine management act" fully implemented the general secretary Xi Jinping's "four most stringent" requirements of the drug, and will strictly supervise the whole process, all links and omnibearing aspects of the vaccine so as to ensure the safety, effectiveness and accessibility of the vaccine, further enhance the quality of vaccine in China, and enhance people's confidence in vaccine safety Jiao Hong said that vaccines are special drugs and national strategic and public welfare products According to the characteristics of vaccines, the vaccine management law clearly puts forward the strictest national management system for vaccines, and puts forward special systems and regulations for the whole process of vaccine development, production, circulation and vaccination At the same time, for the production and sale of fake and inferior vaccines and other illegal acts, the punishment is far higher than that of ordinary drugs, which clearly punishes people, and severe qualification punishment, property punishment and free punishment are given to those who violate the law Jiao Hong stressed that the vaccine management law takes into account safety, development and innovation In order to promote the further improvement of vaccine quality in China, a series of new regulations are made in the vaccine management law to encourage the innovation and development of vaccines First, the State supports basic and applied vaccine research, promotes vaccine development and innovation, and integrates vaccine development, production and storage for prevention and control of major diseases into national strategies Second, the State formulates development plans and industrial policies for the vaccine industry, supports the development and structural optimization of the vaccine industry, encourages the large-scale and intensive production of vaccines, and continuously improves the production process and quality level of vaccines Third, according to the epidemic situation of the disease and the immune status of the population, the State formulates relevant research and development plans, arranges necessary funds, supports the research and development of new vaccines such as multi linked and multi valent vaccines, organizes the holders of vaccine marketing licenses, scientific research units and medical institutions to jointly tackle key problems, and develops vaccines urgently needed for disease prevention and control Fourth, encourage the holders of vaccine marketing license to increase the investment of research and innovation funds, optimize the production process, improve the quality control level, and promote the technological progress of vaccines At the same time, priority should be given to the review and approval of innovative vaccines Jiao Hong also pointed out that since the founding of the people's Republic of China, especially since the reform and opening up, China's vaccine industry has made rapid development, and is one of the few countries in the world that can rely on their own ability to solve all the EPI Vaccines China has passed the evaluation of the national vaccine regulatory system of the World Health Organization twice in 2011 and 2014, and is now preparing to accept a new round of evaluation of the World Health Organization We should take the "vaccine management law" as an opportunity to comprehensively improve China's drug and vaccine regulatory system, strengthen regulatory capacity, better serve the development of the vaccine industry, protect the safety of people's drug use, and promote China to become a vaccine power from a vaccine power Yuan Lin, director of the drug regulatory department of the State Food and drug administration, Yuan Jie, director of the administrative law office of the law working committee of the Standing Committee of the National People's Congress, and Cui Gang, deputy inspector of the disease control and Prevention Bureau of the national health and Health Commission, attended the conference, and respectively answered questions such as the whole process electronic traceability system of vaccine, legal responsibility, vaccination and ensuring the safety of vaccination (live picture and text broadcast on the people's Congress of China: http:// HTM)